Regenerative Medicine Advanced Therapy (RMAT) designation

Regenerative medicine recommended reads including $191 million to researcher

/ / 4 Comments
Mark-Pennesi-CRISPR-regenerative-medicine-eye

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as […]

Regenerative medicine recommended reads including $191 million to researcher Read More »

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

/ / 2 Comments
Peter-Marks-Regenerative-Medicine-Advanced-Therapy-Designation-RMAT-

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »

My new Cell Stem Cell piece: too much carrot & not enough stick on stem cell oversight

/
carrot-and-sticks

I have a new Cell Stem Cell piece out today that aims to take stock of today’s stem cell regulatory oversight in the U.S., Japan, and elsewhere including Australia, Canada and India. I use a carrot and stick metaphor for encouraging legit research and taking regulatory action on serious non-compliant activities, respectively. Where is stem cell

My new Cell Stem Cell piece: too much carrot & not enough stick on stem cell oversight Read More »

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.